Immunothérapie des glioblastomes

Capucine Baldini; Patricia Martin Romano; Andreea Varga; Stéphane Champiat; Sarah Dumont; Frédéric Dhermain; Guillaume Louvel; Aurélien Marabelle; Sophie Postel-Vinay; Eric Angevin; Anas Gazzah; Vincent Ribrag; Rastio Bahleda; Jean Marie Michot; Antoine Hollebecque; Jean Charles Soria; Christophe Massard

doi:10.1016/S0007-4551(18)30391-6

Immunothérapie des glioblastomes

Capucine Baldini, Patricia Martin Romano, Andreea Varga, Stéphane Champiat, Sarah Dumont, Frédéric Dhermain, Guillaume Louvel, Aurélien Marabelle, Sophie Postel-Vinay, Eric Angevin, Anas Gazzah, Vincent Ribrag, Rastio Bahleda, Jean Marie Michot, Antoine Hollebecque, Jean Charles Soria, Christophe Massard

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

Résumé

Immunotherapy in glioblastomas: Targeting the immune system as a therapeutic strategy in solid tumors has shown great efficacy in various tumor types. However the role and success of this approach in glioblastomas remain to be determined. Recent studies demonstrated that central nervous system is no longer considered as an immunoprivileged sanctuary with impressive immune response without blood brain barrier's disruption. Improving our understanding of immune privilege in the central nervous system could lead to better treatment strategies in gliobastomas. This review focuses on describing the immune system in the central nervous system and immuno-therapeutic strategies under development in glioblastomas.

Titre traduit de la contribution	Immunotherapy in glioblastomas
langue originale	Français
Pages (de - à)	S59-S67
journal	Bulletin du Cancer
Volume	105
Les DOIs	https://doi.org/10.1016/S0007-4551(18)30391-6
état	Publié - 1 déc. 2018

mots-clés

CNS
Glioblastoma
Immune checkpoint
Immunotherapy
inhibitors

Accès au document

10.1016/S0007-4551(18)30391-6

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{5be2003d78884afa8c72e52501199339,

title = "Immunoth{\'e}rapie des glioblastomes",

abstract = "Immunotherapy in glioblastomas: Targeting the immune system as a therapeutic strategy in solid tumors has shown great efficacy in various tumor types. However the role and success of this approach in glioblastomas remain to be determined. Recent studies demonstrated that central nervous system is no longer considered as an immunoprivileged sanctuary with impressive immune response without blood brain barrier's disruption. Improving our understanding of immune privilege in the central nervous system could lead to better treatment strategies in gliobastomas. This review focuses on describing the immune system in the central nervous system and immuno-therapeutic strategies under development in glioblastomas.",

keywords = "CNS, Glioblastoma, Immune checkpoint, Immunotherapy, inhibitors",

author = "Capucine Baldini and Romano, {Patricia Martin} and Andreea Varga and St{\'e}phane Champiat and Sarah Dumont and Fr{\'e}d{\'e}ric Dhermain and Guillaume Louvel and Aur{\'e}lien Marabelle and Sophie Postel-Vinay and Eric Angevin and Anas Gazzah and Vincent Ribrag and Rastio Bahleda and Michot, {Jean Marie} and Antoine Hollebecque and Soria, {Jean Charles} and Christophe Massard",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Masson SAS",

year = "2018",

month = dec,

day = "1",

doi = "10.1016/S0007-4551(18)30391-6",

language = "Fran{\c c}ais",

volume = "105",

pages = "S59--S67",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Immunothérapie des glioblastomes

AU - Baldini, Capucine

AU - Romano, Patricia Martin

AU - Varga, Andreea

AU - Champiat, Stéphane

AU - Dumont, Sarah

AU - Dhermain, Frédéric

AU - Louvel, Guillaume

AU - Marabelle, Aurélien

AU - Postel-Vinay, Sophie

AU - Angevin, Eric

AU - Gazzah, Anas

AU - Ribrag, Vincent

AU - Bahleda, Rastio

AU - Michot, Jean Marie

AU - Hollebecque, Antoine

AU - Soria, Jean Charles

AU - Massard, Christophe

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Immunotherapy in glioblastomas: Targeting the immune system as a therapeutic strategy in solid tumors has shown great efficacy in various tumor types. However the role and success of this approach in glioblastomas remain to be determined. Recent studies demonstrated that central nervous system is no longer considered as an immunoprivileged sanctuary with impressive immune response without blood brain barrier's disruption. Improving our understanding of immune privilege in the central nervous system could lead to better treatment strategies in gliobastomas. This review focuses on describing the immune system in the central nervous system and immuno-therapeutic strategies under development in glioblastomas.

AB - Immunotherapy in glioblastomas: Targeting the immune system as a therapeutic strategy in solid tumors has shown great efficacy in various tumor types. However the role and success of this approach in glioblastomas remain to be determined. Recent studies demonstrated that central nervous system is no longer considered as an immunoprivileged sanctuary with impressive immune response without blood brain barrier's disruption. Improving our understanding of immune privilege in the central nervous system could lead to better treatment strategies in gliobastomas. This review focuses on describing the immune system in the central nervous system and immuno-therapeutic strategies under development in glioblastomas.

KW - CNS

KW - Glioblastoma

KW - Immune checkpoint

KW - Immunotherapy

KW - inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85059099675&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(18)30391-6

DO - 10.1016/S0007-4551(18)30391-6

M3 - Article

C2 - 30595200

AN - SCOPUS:85059099675

SN - 0007-4551

VL - 105

SP - S59-S67

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -